Follow siRNA, ASOs, splice modulation, conjugation, delivery, analytics, and manufacturing.
Do not classify every RNA technology as mRNA. Separate payload, delivery route, tissue, species, and development stage.
Sources, selection, and corrections →Verified against public sources, selective and unranked. Drug developers and service providers are labeled separately. Unverified financing, founding dates, and current pipeline stages are not inferred.
DRUG DEVELOPERAlnylam develops RNA interference medicines and presents its delivery platforms, marketed products, clinical programs, and scientific materials on its official website. This profile identifies a drug developer, rather than a contract service provider.
Sources checked: 2026-11-04
Profile & sources →
DRUG DEVELOPERIonis describes a portfolio of RNA- and DNA-targeted medicines, with separate pipeline, medicines, clinical-trial, and scientific-publication resources. Product-specific mechanisms and development status should be checked against dated disclosures.
Sources checked: 2026-11-04
Profile & sources →
DRUG DEVELOPERWave develops RNA-targeting medicines using RNA interference and RNA editing approaches. Its October 27, 2026 update describes WVE-007 as an investigational GalNAc-siRNA and WVE-006 as an investigational RNA-editing oligonucleotide. These are distinct modalities, not mRNA products.
Sources checked: 2026-11-04
Profile & sources →
DRUG DEVELOPERArrowhead develops RNAi therapeutics using its TRiM platform, which combines RNA triggers, targeting ligands, linkers, and chemical modifications. Liver and extrahepatic programs must be assessed by candidate and indication.
Sources checked: 2026-11-04
Profile & sources →
DRUG DEVELOPERSilence Therapeutics develops siRNA medicines through its mRNAi GOLD platform. The name refers to RNA interference and gene silencing; it should not be classified as an mRNA-expression platform.
Sources checked: 2026-11-04
Profile & sources →
DRUG DEVELOPERDyne describes its FORCE platform as a transferrin-receptor-binding Fab, linker, and therapeutic payload for muscle and CNS delivery. Oligonucleotide conjugation and candidate-specific clinical results should be assessed separately.
Sources checked: 2026-11-04
Profile & sources →Original online dates are retained. Guides use accessible articles or abstracts and do not replace reading the paper.
This review examines RNA species, structure and function, chemical modifications, and delivery systems in the context of therapeutic development. It connects molecular design with stability and distribution and discusses clinical applications available at the time of writing. Its historical approval overview should not be interpreted as a current, exhaustive drug list.
Dalton W Staller; Flobater I Gawargi; Sanjali S Panigrahi; Paras K Mishra; Ram I Mahato
DOI: 10.1016/j.pharmr.2025.100065
Manually selected historical and recent original announcements, not presented as today’s news. Source dates, including historical dates, are retained.
Wave's quarterly update describes planning for a registrational WVE-006 RNA-editing study in AATD and ongoing WVE-007 siRNA Phase 2a work. The company also reports FDA support for its LC-MS assay in the planned WVE-006 program. Regulatory feedback and trial plans do not constitute marketing approval or comparative efficacy evidence.
Original announcement ↗